FRAGOMENO, BENEDETTA
FRAGOMENO, BENEDETTA
DIPARTIMENTO DI MEDICINA SPECIALISTICA, DIAGNOSTICA E SPERIMENTALE (attivo dal 28/10/2011 al 31/12/2022)
A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents
2022 Rizzo A.; Oderda M.; Mollica V.; Merler S.; Morelli F.; Fragomeno B.; Taveri E.; Sorgentoni G.; Santoni M.; Massari F.
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis
2022 Santoni M.; Rizzo A.; Mollica V.; Rosellini M.; Marchetti A.; Fragomeno B.; Battelli N.; Massari F.
Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
2021 Dall'Olio FG, Calabrò D, Conci N, Argalia G, Marchese PV, Fabbri F, Fragomeno B, Ricci D, Fanti S, Ambrosini V, Ardizzoni A.
PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors
2021 Dall'Olio F.G.; Gelsomino F.; Conci N.; Marcolin L.; De Giglio A.; Grilli G.; Sperandi F.; Fontana F.; Terracciano M.; Fragomeno B.; Tober N.; Manferrari G.; Brocchi S.; Golfieri R.; Fiorentino M.; Ardizzoni A.
ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world data
2020 Dall'Olio F.G.; Maggio I.; Massucci M.; Mollica V.; Fragomeno B.; Ardizzoni A.